Suppression of Sleeping Beauty -induced Gliomagenicity in Ts1Cje Mice, a Model of Down Syndrome

Keiichi Ishihara,Ryuto Sakoda,Masako Mizoguchi,Mitsugu Fujita,Chiami Moyama,Yuri Okutani,Kazuyuki Takata,Miwa Tanaka,Takashi Minami,Haruhiko Sago,Kazuhiro Yamakawa,Takuro Nakamura,Eri Kawashita,Satoshi Akiba,Susumu Nakata,KEIICHI ISHIHARA,RYUTO SAKODA,MASAKO MIZOGUCHI,MITSUGU FUJITA,CHIAMI MOYAMA,YURI OKUTANI,KAZUYUKI TAKATA,MIWA TANAKA,TAKASHI MINAMI,HARUHIKO SAGO,KAZUHIRO YAMAKAWA,TAKURO NAKAMURA,ERI KAWASHITA,SATOSHI AKIBA,SUSUMU NAKATA
DOI: https://doi.org/10.21873/anticanres.16836
2024-02-01
Anticancer Research
Abstract:BACKGROUND/AIM: Individuals with Down syndrome (DS), attributed to triplication of human chromosome 21 (Hsa21), exhibit a reduced incidence of solid tumors. However, the prevalence of glioblastoma among individuals with DS remains a contentious issue in epidemiological studies. Therefore, this study examined the gliomagenicity in Ts1Cje mice, a murine model of DS.MATERIALS AND METHODS: We employed the Sleeping Beauty transposon system for the integration of human oncogenes into cells of the subventricular zone of neonatal mice.RESULTS: Notably, Sleeping Beauty-mediated de novo murine gliomagenesis was significantly suppressed in Ts1Cje mice compared to wild-type mice. In glioblastomas of Ts1je mice, we observed an augmented presence of M1-polarized tumor-associated macrophages and microglia, known for their anti-tumor efficacy in the early stage of tumor development.CONCLUSION: Our findings in a mouse model of DS offer novel perspectives on the diminished gliomagenicity observed in individuals with DS.
oncology
What problem does this paper attempt to address?